Introduction {#sec1-2048004019869162}
============

More than 15 million strokes occur worldwide every year and the importance of the timing of treatment for acute events is nowadays well known. Evidence showed poor efficacy of current pharmacological treatment of acute stroke (AS), with low rate of recanalization, especially in case of major vessel occlusions.

On the other hand, percutaneous treatments of AS and acute myocardial infarction (the last routinely performed) present several similarities, and the importance of an invasive management for acute neurological events is currently debated.

Case report {#sec2-2048004019869162}
===========

A 74-year-old male, smoker, diabetic with previous acute coronary syndrome and stent implantation in the right coronary artery (RCA), was admitted to our Cath-lab for non-ST-elevation myocardial infarction. Despite detailed information about the life-threatening risk and the importance to immediately undergo percutaneous coronary intervention (PCI), the patient refused the procedure and self-discharged.

Two weeks later, he presented to the emergency department for major stroke, unconscious, aphasic with right hemiplegia (NIHSS 27). Furthermore, his electrocardiogram showed massive ST-segment elevation in inferior-lateral leads, with specular anterior ST depression, signs of a concomitant inferior-posterior-lateral STEMI. Blood pressure was 170/80 mmHg, Killip class 1 and time-from-onset of stroke symptoms was established to be within 2 h. CT angiogram of supra-aortic vessels confirmed the occlusion of the left internal carotid artery (ICA) excluding hemorrhagic cerebral infarction ([Figure 1(a)](#fig1-2048004019869162){ref-type="fig"}).

![CT angiography of supra-aortic vessels showing the occlusion of the left internal carotid artery (a, arrow). Carotid angiogram showing the occlusion at the origin of the left internal carotid artery (b).](10.1177_2048004019869162-fig1){#fig1-2048004019869162}

We decided to perform a complete percutaneous treatment for both the cerebral and myocardial acute ischemic events. Coronary angiography confirmed a proximal occlusion of the RCA, whereas carotid angiogram showed the occlusion at the origin of the left ICA ([Figure 1(b)](#fig1-2048004019869162){ref-type="fig"}). After providing double proximal and distal cerebral protection with both filter-wire and MOMA system, we first performed thrombus aspiration and then proceeded with stent implantation in the ICA ([Figure 2 (a)](#fig2-2048004019869162){ref-type="fig"}). A cerebral angiogram, performed to check the status of intracranial vessels, highlighted clot embolization in the middle cerebral artery ([Figure 2(b)](#fig2-2048004019869162){ref-type="fig"}) requiring immediate revascularization with 2.0/15 mm balloon angioplasty ([Figure 2(c)](#fig2-2048004019869162){ref-type="fig"}). Finally, we completed the revascularization with PCI and bare metal stent positioning in the RCA, with flow restoration and resolution of ST elevation. Patient\'s clinical conditions improved significantly in the following hours; however, pharmacological sedation for psychomotor agitation was required for 48 h. Dual antiplatelet therapy based on acetylsalicylic acid (100 mg) and clopidogrel (75 mg) was immediately started with loading dose administration. Low-molecular weight heparin was also continued during hospitalization and for the following two weeks. On day 5, functional recovery of the right arm occurred, and on day 7, he achieved complete movement restoration with residual aphasia (NIHSS 13).

![Carotid angiogram performed through the MOMA proximal protection system, showing flow restoration after stent implantation in the internal carotid artery (a). Cerebral angiogram of intracranial vessels, showing clot embolization in the middle cerebral artery (b). Middle cerebral artery after revascularization by balloon PTA (c).](10.1177_2048004019869162-fig2){#fig2-2048004019869162}

Discussion and review of the literature {#sec3-2048004019869162}
=======================================

Current standard treatment of AS is represented by administration of tissue plasminogen activator (tPA), with several limitations in terms of short therapeutic time window (within 4.5 h of symptom onset) and exclusion criteria such as evidence or history of intracranial hemorrhage, severe uncontrolled hypertension, recent surgery, head trauma or stroke in the previous three months, and coagulopathy.^[@bibr1-2048004019869162]^ Moreover, some evidence showed poor efficacy of this treatment in AS due to big-size proximal vessels occlusions (i.e. middle cerebral artery), with low rate of recanalization, depending on high thrombus length (\>8 mm).

Percutaneous treatment of AS, as shown in our case report, has several similarities to the "primary" treatment of acute myocardial infarction, and its importance has been much debated in the past years. It includes both local infusion of tPA for clot dissolution and mechanical recanalization by thrombus aspiration or retrieval with dedicated devices.

Due to the infrequence of contemporary onset of AS and STEMI, a specific antithrombotic regimen is not recognized for this setting. As always preferable it should be tailored on individual patients' ischemic and hemorrhagic risks. In our case, the choice to administer clopidogrel instead of newer P2Y12 inhibitors was based on the presence of acute stroke (ruling out Prasugrel) with rapid evolution of the clinical setting and high risk of hemorrhagic progression (ruling out ticagrelor).^[@bibr2-2048004019869162]^

Recently, several studies evaluated the effects of endovascular strategy vs. thrombolysis on clinical outcomes, and interesting meta-analysis further examined these data.^[@bibr3-2048004019869162],[@bibr4-2048004019869162]^ Eight multicenter randomized trials, enrolling more than 2400 patients, have been published between 2013 and 2015; about 1300 patients underwent endovascular treatment and 1100 received standard medical therapy. Mechanical thrombectomy showed improvement in terms of functional outcomes and angiographic revascularization at 24 h, especially in cases of proximal arterial occlusion and using stent-retriever devices; there were no differences about intracranial hemorrhage incidence and mortality at 90 days in the overall population ([Table 1](#table1-2048004019869162){ref-type="table"}).

###### 

Results from the most important randomized trials comparing endovascular vs medical treatment of acute stroke.

![](10.1177_2048004019869162-table1)

  RCTs                   Functional independence (mRS: 0--2) at 90 days   Revascularization at 24 h   Symptomatic intracranial hemorrhage within 90 days                                                                                                         
  ---------------------- ------------------------------------------------ --------------------------- ---------------------------------------------------- -------- --------- --------- ---------------------- -------- --------- --------- -------------------- -------
  2013 Negative Trials                                                                                                                                                                                                                                           
   SYNTHESIS             76/181                                           84/181                      0.84 (0.55--1.27)                                    .40      --        --        --                     --       10/181    10/181    1.00 (0.41--2.46)    \>.99
   MR RESCUE             12/64                                            11/54                       0.90 (0.36--2.25)                                    .82      --        --        --                     --       3/64      2/54      1.28 (0.21--7.95)    .79
   IMS III               177/415                                          86/214                      1.11 (0.79--1.55)                                    .55      --        --        --                     --       27/434    13/222    1.07 (0.54--2.11)    .85
  2015 Positive Trials                                                                                                                                                                                                                                           
   MR CLEAN              76/233                                           51/267                      2.05 (1.36--3.09)                                    .001     141/187   68/207    6.27 (4.03--9.74)      \<.001   18/233    17/267    1.23 (0.62--2.45)    .55
   ESCAPE                87/164                                           43/147                      2.73 (1.71--4.37)                                    \<.001   113/156   43/138    5.81 (3.51--9.60)      \<.001   6/165     4/150     1.38 (0.38--4.98)    .63
   EXTEND-IA             25/35                                            14/35                       3.75 (1.38--10.17)                                   .009     33/35     15/35     22.00 (4.55--106.43)   \<.001   0/35      2/35      0.19 (0.01--4.08)    .29
   SWIFT-PRIME           59/98                                            33/93                       2.75 (1.53--4.94)                                    .001     53/64     21/52     7.11 (3.03--16.7)      \<.001   1/98      3/97      0.32 (0.03--3.16)    .33
   REVASCAT              45/103                                           29/103                      1.98 (1.11--3.53)                                    .02      --        --        --                     --       5/103     2/103     2.58 (0.49--13.59)   .27
  Overall                557/1293                                         351/1094                    1.71 (1.18--2.49)                                    .005     340/442   147/432   6.49 (4.79--8.79)      \<.001   70/1313   53/1109   1.12 (0.77--1.63)    .56

mRS: modified Rankin Scale; RCT: randomized controlled trial.

The three previous trials (SYNTHESIS, MR RESCUE, and IMS III) published in 2013 reported negative data for endovascular intervention, showing no significant benefit over thrombolysis.^[@bibr5-2048004019869162][@bibr6-2048004019869162]--[@bibr7-2048004019869162]^ However, major limitations of these studies were inaccurate randomization (non-imaging guided for low availability of CT angiography), variable use of tPA in the endovascular treatment group, and use of outdated (first-generation) mechanical thrombectomy devices.

The five more recent trials (MR-CLEAN, ESCAPE, EXTEND-IA, SWIFT-PRIME, and REVASCAT) published in 2015 have overcome these limitations showing a relative benefit of endovascular interventions further increased by the association of tPA, over thrombolysis alone.^[@bibr8-2048004019869162][@bibr9-2048004019869162][@bibr10-2048004019869162]--[@bibr11-2048004019869162]^ Routine use of newer stent-retriever devices for thrombectomy, as well as the time to treatment, significantly influenced the efficacy of this treatment in recent trials. Current guidelines recommend performing endovascular treatment, for all patients with AS caused by a major artery occlusion, possibly within 6 h from symptom onset. A recent meta-analysis from the HERMES group identified a significant benefit of treatment, in terms of lower degrees of disability at three months (modified Rankin Scale, mRS score of 0--2), for procedures started within 7.3 h after symptom onset.^[@bibr12-2048004019869162]^

The importance of the "timing" for treatment of AS is nowadays common knowledge, so that the principle "time is muscle" has been translated to "time is brain," and interventional cardiologists could play a crucial role to effectively respond to this healthcare challenge.

The recently published PRAGUE-16 Registry evaluated the feasibility and safety of direct endovascular thrombectomy, not preceded by tPA, performed by cardiologists in Interventional Cardiology department, in cooperation with neurologists and radiologists.^[@bibr13-2048004019869162]^ It was a prospective, observational pilot registry, including 103 patients with less than 6 h onset of AS and CT scan evidence of major artery occlusion without large cerebral ischemia; patients were treated by direct catheter-based thrombectomy (73 patients) vs. double treatment with tPA plus endovascular intervention (30 patients), based on clinical picture and CT scan. Similar results have been achieved in both groups, with good functional recovery (mRS score of 0--2 at 90 days) in about 40% of patients, interesting if compared with only 30% recovery in patients who received medical treatment alone (tPA) in previous trials.

Conclusions {#sec4-2048004019869162}
===========

Direct catheter-based thrombectomy, if performed within the appropriate window of time in selected patients, represents a valid and faster alternative to thrombolysis (alone or bridging to the intervention). Because of the lack of an organized Interventional Neuroradiology service in many countries, dedicated to 24 h treatment of AS, interventional cardiologists with their consolidated experience in endovascular procedures could be involved in this network, in a multidisciplinary effort targeted to the setting up of a stroke management system.
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